Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the Society for Neuroscience (SFN) 2016 Annual Meeting, taking place November 12-16, 2016 in San Diego, CA.

Below is the schedule for the presentations:

Date: Saturday, November 12, 2016 Poster Presentation Time: 1:00 p.m. - 5:00 p.m. PT Location: Halls B-H, San Diego Convention Center Poster Number: 34.04 / E6 Title: Pharmacology of the human e subunit from the GABA A receptors

Date: Monday, November 14, 2016 Poster Presentation Time: 1:00 p.m. - 4:00 p.m. PT Location: Halls B-H, San Diego Convention Center Poster Number: 407.11 / K17 Title: Neuroactive steroids exhibit synergistic interactions with barbiturates at the GABA A receptor in vitro and this impacts on activity in an animal model of seizure

Date: Tuesday, November 15, 2016 Poster Presentation Time: 8:00 a.m. - 12:00 p.m. PT Location: Halls B-H, San Diego Convention Center Poster Number: 497.10 / F21 Title: Positive allosteric modulation of NMDA receptors ameliorate behavioral and electrophysiological phenotypes in a pre-clinical model of Smith-Lemli-Opitz Syndrome

Date: Wednesday, November 16, 2016 Poster Presentation Time: 8:00 a.m. - 12:00 p.m. PT Location: Halls B-H, San Diego Convention Center Poster Number: 690.11 / L8 Title: Phenytoin halts convulsions, but not electrographic seizure activity, in a rat model of status epilepticus, whereas both are eliminated by next generation neuroactive steroids

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161110006437/en/

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX